HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.
Mark D. Pegram, MD


What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.

Mark D. Pegram, MD Released: July 23, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?